Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Slides:

Advertisements

Similar presentations

Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.

Statements on Head and Neck Cancer 2006 Primary Radiochemotherapy Arlene A. Forastiere, M.D. Johns Hopkins University School of Medicine Department of.

CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Esophageal Cancer, New updates in Chemoradiation Dr Hamid Reza Dehghan Manshadi Radiation Oncologist Iran University of Medical sciences.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.

Hot topics in breast radiotherapy Mark Beresford.

AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.

Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.

GIC Protocol Meeting Ca Stomach Presentor-Dr Richa Madhawi Moderator- Dr S. Pathy.

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

LUNG CANCER Dr.Mohammadzadeh. Lung cancer is the leading cancer killer in the United States. Every year, it accounts for 30% of all cancer deaths— more.

Proton Therapy for Chondrosarcomas of the Skull Base and Cervical Spine: Long-term Experience at Loma Linda University Medical Center D. Y. Kim 2, R. W.

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

Cardiac events after treatment with high dose radiation therapy +/- chemotherapy for non-small cell lung cancer Linglong Tang, Anwen Liu, Daniel Gomez,

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.

PHASE I TRIAL OF CONCURRENT CHEMORADIOTHERAPY USING DOXIFLURIDINE AND PACLITAXEL IN ADVANCED BREAST CANCER H.Hirowatari 1, K. Karasawa 1,2,

Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Intensity-Modulated Radiotherapy is Associated with Improved Global Quality of Life Among Long-Term Survivors of Head and Neck Cancer Allen M. Chen, M.D.,

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.

Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Bladder Cancer R. Zenhäusern.

Multi-station N2 Ca Lung

Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma Sachiko Yamamoto MD,

Short-term outcome of neo-adjuvant chemotherapy

Results of Definitive Radiotherapy in Anal Canal Carcinoma

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

Prognosis of younger patients in non-small cell lung cancer

Institute of Oncology “Ion Chiricuță”, Cluj, Romania

Adjuvant Radiation is Required for Gastric Cancer

ACT II: The Second UK Phase III Anal Cancer Trial

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

Neoadjuvant Adjuvant Curative Palliative

Surgical resection of metachronous liver metastases

Bradford Hoppe MD, MPH William Hartsell, MD

Presentation transcript:

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo, K. Hiroi, T. Shibata T. Nishikawa, H. Shiozaki* Department of Radiation Oncology and Surgery*, Kinki University School of Medicine

・ Failure pattern in definitive chemoradiotherapy (CRT) for esophageal cancer were analyzed to evaluate the appropriateness of our RT field. Purpose

Patients Characteristics From 1999 to 2006, 136 consecutive patients with esophageal cancer with localized esophageal cancer were treated with definitive CRT at our hospital. Age ； 38 ~ 82 years old （ median; 64 years ） Gender; men ： females =116 ： 20 PS 0/ 1/ 2 /3= 58/ 66/ 11/ 1 Histology; 135 pts squamous cell carcinomas 1 pt adenocarcinoma Stage; I ： II ： III: IV= 8 ： 25 ： 76: 27 (2002 UICC) T Factor T1:T2:T3 ： T4 =15:20:27 ： 74, N Factor N0 ： N1 = 27 ： 109 Location of primary tumor: Ce: Ut: Mt: Lt = 19: 27: 71: 19 Tumor length ： 1 ~ 19cm （ median 6.5cm ）

Initial RT Fields according to the primary site ・ Cervical esophagus (Ce) Bilateral neck and subcarinal LNs (Short T-shaped Field) ・ Upper (Ut) and middle (Mt) esophagus Bilateral neck and whole mediastinal LNs (T-shaped Field) ・ Lower esophagus (Lt) Whole mediastinal LNs and perigastric LNs (I-shaped Field)

Initial RT Fields CeUt, Mt Lt

Radiation and Chemotherapy ・ Radiation therapy 60 Gy/30 fr/7 w (one-week split) for the both groups. Either a 6 MV or 10 MV X-ray was used. Boost was given following 40 Gy. ・ Two courses of concurrent CT were combined with RT Ⅰ、 low-dose protracted pattern 102 pts （ 75% ） CDDP 7mg/m 2 × 10 days 5-FU mg/m 2 × 14 days Ⅱ、 high-dose pattern 34 pts （ 25% ） CDDP 70mg/m 2 × 1 day 5-FU 700mg/m 2 × 5 days After CRT, 1-2 courses of adjuvant CT of cisplatin/5-FU were given for 75 pts (55%).

Results ・ A total dose of 60 Gy could be delivered for 133 pts (98%). ・ 2 courses of planned CT could be combined concurrently with RT for 118 pts (87%). ・ Complete response （ CR ） in the RT field was achieved in 84 pts （ 62% ）. T1 15/15 （ 100% ） T2 18/20 （ 90% ） T3 20/27 （ 74% ） T4 31/72 （ 42% ）・ Failure Pattern of the 84 pts with CR was evaluated.

Overall survival T1N0M0 n=8 2-year survival 100 ％ 5-year survival 80 ％ month

Overall survival stages II-III (excluding T4) n=39 2-year survival 59% 5-year survival 41% month

Overall survival, stages III-IV T4 or M1- ｌｙｍｐｈ n=84 2-year survival 26% 5-year survival 19% month

CR (n=84) Overall survival rate ; year survival 66% 5-year survival 52% Non-CR (n=52) month

Failure pattern (n=84) No rec. 39 pts (46%) In-field rec. 12 pts (14%) Out-field rec. 33 pts (40%) Isolated marginal rec. 9 pts (11%) Distant meta ±regional LN Rec. 24 pts (29%)

Treatment results for 9 pts with isolated marginal recurrences Lower esophageal （ out of RT Field ） rec. ２ pts （ Origin: Ce 、 Ut ） Salvage surgery was performed for 2 pts. ⇒ Local control could be achieved Lymph node rec. (out of RT Field) ７ pts Perigastric LN recurrence 4 pts Lymph node dissection 2 ｐｔｓ 2nd-CRT(50-60Gy) 2 ｐｔｓ ⇒ Local control could be achieved Hilar LN rec. 2 pts Neck + retrocrural LNs １ pt 2nd-CRT(50-60Gy) 3 ｐｔｓ Local control could not be achieved. In all 6 pts with lower esophageal or perigastric LNs recurrence,salvage treatments were successful. In all 6 pts with lower esophageal or perigastric LNs recurrence, salvage treatments were successful. Local control could be achieved Local control could not be achieved. ⇒

Late toxicities (n=84) RTOG/EORTC *: CTCAE version 3.0 Grade G1G2G3G4 =>G2 Esophagus (11%) Heart (2%) Lung (6%) Spinal cord10000 (0%) Pleural* (1%) Hypothyroid*13104 (5%) Renal failure* (1%) Pt. Max. # (23%)

Conclusions The 5-year overall survival rates of definitive CRT of 60Gy for both resectable and unresectable esophageal cancer were excellent. Although recurrences after initial CR were noted frequently, salvage treatments were successful for isolated marginal recurrences in the lower esophagus or perigastric LNs. For Ce, Ut and Mt tumors, lower esophageal and perigastric LN region can be excluded from the initial RT field.